One could expect an enhancement of the type 1 IFN response seen in the R47H to be a beneficial mutation if it means a more aggressive containment of the virus, but this could also be interpreted as an overactive immune response that leads to enhanced collateral damage
No organ damage, no hormonal disruption, no carcinogenic signals

For anxiety relief (primary use) Beginner dose (first week): 250mcg once daily Subcutaneous injection Morning or early afternoon Assess tolerance and response Standard dose (most people): 500mcg once daily Effective for 70-80% of users Subcutaneous injection Morning or afternoon administration Higher dose (severe anxiety): 750-1,000mcg daily Split into two doses (500mcg morning, 500mcg afternoon) For severe generalized anxiety or panic disorder Not necessary for most users Maximum dose: 2,000mcg (2mg) daily Rarely needed Only if lower doses insufficient Should be split into 2-3 doses Dosing progression: Week 1: 250mcg daily Week 2-4: Increase to 500mcg if needed Week 4+: Increase to 750-1,000mcg only if 500mcg insufficient Expected anxiety relief: Mild anxiety: 250-500mcg usually sufficient Moderate anxiety: 500mcg standard dose Severe anxiety: 750-1,000mcg may be needed 60-80% reduction in anxiety symptoms typical Use our peptide calculator to calculate exact doses and see peptide dosing guide for comprehensive dosing strategies

Step 3 Draft Rule Publication: If the FDA agrees to reclassify compounds, it must draft and publish formal regulatory language a process that takes additional months
This is an active area of research
None are intended for the diagnosis, treatment, cure, or prevention of any human or animal disease